<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">237</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2016-92-3-36-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SHORT COMMUNICATION</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Using clinical and diagnostic indices to assess the severity of pemphigus (a comparative analysis)</article-title><trans-title-group xml:lang="ru"><trans-title>Применение клинико-диагностических индексов в оценке тяжести пузырчатки (сравнительный анализ)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kubanov</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Кубанов</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>abtava@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Abramova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Абрамова</surname><given-names>Т. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center ofDermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian Medical Academy of Postgraduate Studies, Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ГБОУ ДПО РМАПО Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-06-24" publication-format="electronic"><day>24</day><month>06</month><year>2016</year></pub-date><volume>92</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>36</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2017-08-24"><day>24</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Kubanov A.A., Abramova T.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Кубанов А.А., Абрамова Т.В.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Kubanov A.A., Abramova T.V.</copyright-holder><copyright-holder xml:lang="ru">Кубанов А.А., Абрамова Т.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/237">https://vestnikdv.ru/jour/article/view/237</self-uri><abstract xml:lang="en"><p>The article discusses clinical indices suggested for the assessment of the severity of the course of autoimmune bullous dermatosis - pemphigus. These indices make it possible to assess the severity of the disease in view of the localization and prevalence of blisters and/or erosions and patient’s subjective sensations as well as efficacy of the therapy, and to compare the study results. In spite of the great number of indices suggested for the assessment of the severity of pemphigus, none of them are generally recognized. The following indices are currently considered as the best known and most convenient for application in clinical practice: Pemphigus Disease Area Index (PDAI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Vulgaris Activity Score (PVAS). A number of studies demonstrated mutual correlation among ABSIS, PDAI and PVAS. However, the group of patients under examination mainly comprised people suffering from light to moderate forms of pemphigus, which makes it difficult to interpret the results of comparative studies. It is expedient for leading dermatovenerologists to carry out clinical studies based on a large group of patients with pemphigus of different severity to elaborate a common tool to assess the severity of pemphigus in the Russian Federation to be recommended by the Russian Society of Dermatovenerologists.</p></abstract><trans-abstract xml:lang="ru"><p>В статье рассматриваются клинические индексы, предложенные для оценки степени тяжести течения аутоиммунного буллезного дерматоза - пузырчатки. Индексы позволяют объективно оценивать тяжесть течения заболевания с учетом локализации и распространенности пузырей и/или эрозий и субъективных ощущений пациента, эффективность проводимой терапии, сравнивать результаты научных исследований. Несмотря на большое количество предложенных индексов оценки тяжести пузырчатки, ни один из них не является общепризнанным. Наиболее известными и удобными к применению в клинической практике в настоящее время признаются: индекс площади поражения при пузырчатке (PDAI), оценка тяжести аутоиммунных буллезных заболеваний кожи (ABSIS), оценка активности вульгарной пузырчатки (PVAS). В ряде исследований показана корреляция ABSIS, PDAI, PVAS между собой. Однако контингент обследованных пациентов в основном включал больных пузырчаткой с легкой и средней тяжестью заболевания, что затрудняет интерпретацию результатов сравнительных исследований. Представляется целесообразным проведение ведущими специалистами-дерматовенерологами клинических исследований на большом количестве больных пузырчаткой с различной тяжестью заболевания в целях разработки единого инструмента оценки тяжести пузырчатки в Российской Федерации для рекомендаций к использованию Российским обществом дерматовенерологов.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>пузырчатка</kwd><kwd>клинические индексы</kwd><kwd>степень тяжести</kwd><kwd>PDAI</kwd><kwd>ABSIS</kwd><kwd>PVAS</kwd><kwd>pemphigus</kwd><kwd>clinical indices</kwd><kwd>severity</kwd><kwd>PDAI</kwd><kwd>ABSIS</kwd><kwd>PVAS</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Кубанов А.А., знаменская Л.Ф., Абрамова Т.В., Свищенко С.И. К вопросам диагностики истинной акантолитической пузырчатки. Вестн дерматол венерол 2014; 6: 121-130</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Tamgadge S., Tamgadge A., Bhatt D.M., Bhalerao S., Pereira T. Pemphigus vulgaris. Contemp Clin Dent 2011; 2: 134-137</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Grando S.A. Pemphigus autoimmunity: Hypotheses and realities. Autoimmunity 2012; 45: 7-35</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Кубанова А.А., карамова А.Э., Кубанов А.А. Поиск мишеней для таргетной терапии аутоиммунных заболеваний в дерматологии. Вестн росс акад мед наук 2015; 70 (2): 159-164</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Кубанов А.А., Абрамова Т.В. Современные методы терапии истинной акантолитической пузырчатки. Вестн дерматол венерол 2014; 4: 19-27</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Martin L.K., Werth V., Villanueva E., Segall J., Murrell D.F. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; (1): CD006263</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Chams-Davatchi C., Rahbar Z., Daneshpazhooh M., Mortazavizadeh S.M., Akhyani M., Esmaili N., Balighi K. Pemphigus vulgaris activity score and ssessment of convergent validity. Acta Med Iran 2013; 51 (4): 224-230.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Tjokrowidjaja A., Daniel B.S., Frew J.W. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol 2013 Nov; 169 (5): 1000-1006.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhao C.Y., Murrell D.F. Outcome measures for autoimmune blistering diseases. J Dermatol 2015 Jan; 42 (1): 31-36.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hertl M., Jedlickova H., Karpati S., Marinovic B., Uzun S., Yayli S., Mimouni D., Borradori L., Feliciani C., Loannides D., Joly P., Kowalewski C., Zambruno G., Zillikens D., Jonkman M.F. Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J. Eur. Acad Dermatol Venereol 2015; 29 (3): 405-414.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Murrell D.F., Amagai M., Werth V.P. Scoring systems for blistering diseases in practice: why bother, and which one should you use? JAMA dermatology. American Medical Association 2014; 150 (3): 245-247.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Wallace A.B. The exposure treatment of burns. Lancet. 1951; 1: 501-504.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Livingston M.D., Edward H., Lee, B.S. Percentage of Burned Body Surface Area Determination in Obese and Nonobese Patients. J Surg Res 2000; 91 (2): 106-110.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kalra S. Assessment of burn area: Can we be more objective? Burns 2006; 32 (1): 134.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Guzzo C.A., Weiss J.S., Mogavero H.S. et al. A review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatoses. J Am Acad Dermatol 1991; 25 (6), Pt 2.: 1179-1183.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Heald P., Mehlmauer M., Martin A.G., Crowley C.A., Yocum R.C., Reich S.D. Topical bexaro-tene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. Elsevier 2003; 49 (5): 801-815.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Langley R.G., Ellis C.N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51 (4): 563-569.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Hundley J.L., Carroll C.L., Lang W. et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006; 54 (2): 217-220.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rosenbach M., Murrell D.F., Bystryn J.C. et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009 (Oct); 129 (10): 2404-2410.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Daniel B.S., Hertl M., Werth V.P. et al. Severity score indexes for blistering diseases. Clin Dermatol 2012; 30 (1): 108-113.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Ikeda S., Immamara S., Hashimoto I., Morioka S., Sakuma M., Ogawa H. History of the establishment and revision of diagnostic criteria, severity index and therapeutic guidelines for pemphigus in Japan. Arch Dermatol Res 2003; 295, Suppl 1: 12-16.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Benchikhi H., Nani S., Baybay H. et al. Pemphigus: use of the Japanese severity index in 56 Moroccan patients. Pan Afr Med J 2013; 16: 96.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Agarwal M., Walia R., Kochhar A.M., Chander R. Pemphigus Area and Activity Score (PAAS)-a novel clinical scoring method for monitoring of pemphigus vulgaris patients. Int J Dermatol 1998; 37 (2): 158-160.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Адаскевич В.П. количественная оценка степени тяжести дерматозов. Дерматология 2014; 2: 24-31</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mortazavi H., Kiavash K., Esmaili N., Chams-Davatchi C. Correlation of pemphigus vulgaris antibody titers by indirect immunofluorescence with activity of disease based on Pemphigus Area and Activity Score (PAAS). Acta Medicum Iran 2008; 46 (3): 559-564.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Pfütze M., Niedermeier A., Hertl M., Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J dermatology 2007; 17: 4-11.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Grover S. Scoring systems in pemphigus. Indian J Dermatol 2011; 56: 145-149.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Harman K.E., Seed P.T., Gratain M.J., Bhogal B.S., Challacombe S.J., Black M.M. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144 (4): 775-780.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Свирщевская Е.В., Матушевская Е.В., Дзуцева И.Р., Марченко А.Н., Лысенко А.А. Разработка иммуноферментной тест-системы на основе дрожжевого рекомбинантного десмоглеина 3 для серодиагностики вульгарной пузырчатки. Вестн дерматол венерол 2005; 3: 4-10</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ishii K., Amagai M., Hall R.P. et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159(4): 2010-2017.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Herrero-Gonzalez J.E., Iranzo P., Benitez D. et al. Correlation of immunological profile with phenotype and disease outcome in pemphigus. Acta Derm Venereol 2010; 90 (4): 401-405.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Schmidt E., Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10: 84-89.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Дерматология Фицпатрика в клинической практике: в 3 т. Вольф К., Голдсмит Л.А., Кац С.И. и др. Пер. с англ.; общ. ред. акад. А.А. Кубановой. М: Изд-во Панфилова; БИНОМ. Лаборатория знаний 2012; 1; 550-511</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Saraswat A., Bhushan K., India C. A new grading system for oral pemphigus. Int J Dermatol 2003; 42 (5): 413-414</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Mahajan V.K., Sharma N.L., Sharma R.C., Garg G. Twelve-year clinico-therapeutic experience in pemphigus: a retrospective study of 54 cases. Int J Dermatol 2005; 44 (10): 821-827</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Адаскевич В.П. Диагностические индексы в дерматологии. М: Изд-во Панфилова; БИНОМ. Лаборатория знаний 2014; 352</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Kumar B., Arora S., Kumaran M.S. et al. Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus // Ind J Dermatol Venereol Leprol Medknow Publications 2006; 72 (3): 203</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Kautz O., Hertl M., Sticherling M., Zillikens D., Bruckner-Tuderman L. Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227-233</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Колос Ю.В., Лукьянов А.М. Использование клинических индексов для оценки степени тяжести течения пузырчатки. Медицинская панорама. Рецензируемый научно-практический журнал для врачей 2013; 1: 69-74</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Kamiya K., Aoyama Y., Shirafuji Y. et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci 2013 (Jun); 70 (3): 190-195</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Patsatsi A., Kyriakou A., Giannakou A. et al. Clinical significance of anti-desmoglein-1 and -3 circulating autoantibodies in Pemphigus Patients Measured by Area Index and Intensity Score. Acta Derm Venereol 2014; 94 (2): 203-206</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Rahbar Z., Daneshpazhooh M., Mirshams-Shahshahani M. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score. JAMA dermatology 2014; 150 (3): 266-272</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Адаскевич В.П. Диагностические индексы в дерматологии. М, Медицинская книга. 2004: 164</mixed-citation></ref></ref-list></back></article>
